He S, Walls A F
Immunopharmacology Group, Southampton General Hospital, UK.
Eur J Pharmacol. 1997 Jun 5;328(1):89-97. doi: 10.1016/s0014-2999(97)83033-6.
We have investigated the potential of tryptase to stimulate an increase in microvascular permeability following injection into the skin of guinea pigs. Tryptase was isolated from high salt extracts of human lung tissue by octyl-agarose and heparin-agarose chromatography. Injection of purified tryptase (2.5 ng-2.5 microg/site) into the skin of guinea pigs which had been injected intravenously with Evans blue dye provoked a dose-dependent increase in microvascular permeability. The skin reactions elicited by tryptase were apparent up to 80 min following injection, while histamine-induced microvascular leakage resolved completely by 40 min. Heat-inactivation of tryptase, or preincubating the proteinase with certain proteinase inhibitors, significantly reduced the extent of microvascular leakage, suggesting dependency on an intact catalytic site. No evidence was found for a synergistic or antagonistic interaction between tryptase (2.5 ng-2.5 microg/site) and histamine (1-10 microg/site) when these mast cell products were injected together. Addition of heparin to tryptase (10:1; w/w) prior to injection was without effect on tryptase-induced microvascular leakage. Pretreatment of guinea pigs with a combination of the histamine H1 receptor antagonist pyrilamine and the histamine H2 receptor antagonist cimetidine (both 10 mg/kg), partially abolished tryptase-induced microvascular leakage as well as attenuating the reaction to histamine. Reasoning that the microvascular leakage induced by tryptase is likely to involve the release of histamine, we investigated the ability of tryptase to stimulate histamine release from dispersed guinea-pig skin and lung cells in vitro. Tryptase was found to induce concentration-dependent histamine release from both sources of tissue. Mast cell activation stimulated by tryptase in vitro was inhibited by heat treating the enzyme or by addition of proteinase inhibitors, suggesting a requirement for an intact catalytic site. Histamine release was inhibited also by preincubating cells with the metabolic inhibitors antimycin A and 2-deoxy-D-glucose indicating that the mechanism was energy-requiring and non-cytotoxic. We conclude that human mast cell tryptase may be a potent stimulus of microvascular leakage. The activation of mast cells by this proteinase may represent an amplification process in allergic inflammation.
我们研究了将类胰蛋白酶注射到豚鼠皮肤后,其刺激微血管通透性增加的可能性。类胰蛋白酶是通过辛基琼脂糖和肝素琼脂糖层析从人肺组织的高盐提取物中分离得到的。将纯化的类胰蛋白酶(2.5纳克 - 2.5微克/部位)注射到预先静脉注射伊文思蓝染料的豚鼠皮肤中,可引起微血管通透性呈剂量依赖性增加。类胰蛋白酶引起的皮肤反应在注射后长达80分钟内都很明显,而组胺诱导的微血管渗漏在40分钟时完全消退。类胰蛋白酶的热灭活,或用某些蛋白酶抑制剂对该蛋白酶进行预孵育,可显著降低微血管渗漏的程度,表明其依赖于完整的催化位点。当将这些肥大细胞产物一起注射时,未发现类胰蛋白酶(2.5纳克 - 2.5微克/部位)与组胺(1 - 10微克/部位)之间存在协同或拮抗相互作用。在注射前向类胰蛋白酶中添加肝素(10:1;重量/重量)对类胰蛋白酶诱导的微血管渗漏没有影响。用组胺H1受体拮抗剂吡苄明和组胺H2受体拮抗剂西咪替丁(均为10毫克/千克)联合预处理豚鼠,可部分消除类胰蛋白酶诱导的微血管渗漏,并减轻对组胺的反应。由于推测类胰蛋白酶诱导的微血管渗漏可能涉及组胺的释放,我们研究了类胰蛋白酶在体外刺激分散的豚鼠皮肤和肺细胞释放组胺的能力。发现类胰蛋白酶可诱导这两种组织来源的组胺浓度依赖性释放。体外类胰蛋白酶刺激的肥大细胞活化可通过对酶进行热处理或添加蛋白酶抑制剂来抑制,表明需要完整的催化位点。组胺释放也可通过用代谢抑制剂抗霉素A和2 - 脱氧 - D - 葡萄糖对细胞进行预孵育来抑制,这表明该机制需要能量且无细胞毒性。我们得出结论,人肥大细胞类胰蛋白酶可能是微血管渗漏的有力刺激物。这种蛋白酶对肥大细胞的激活可能代表了过敏性炎症中的一个放大过程。